Inclusion Criteria:

- Age > 18

- ECOG performance status of 2 or less.

- CLL with a diagnostic score of 4 or 5.

- Clinical stage A disease.

- No disease progression over a minimum of 1 month prior to commencement of therapy.

- Less than 2 adverse prognostic factors.

- Absence of adverse cytogenetics.

- Expected survival > 6 months.

- Able to give informed consent.

- No clinical evidence of active infection at the time of study entry.

- No known allergy to any of the study medications.

- Renal and liver function tests within normal limits.

Exclusion Criteria:

- Disease progression during screening period.

- Known positivity for HIV types 1 or 2.

- Active infection at the time of screening.

- Pregnancy or lactation.

- Females of childbearing potential† and males not willing to practice an effective
method of contraception whilst receiving the antibiotic regimen and for 4 weeks after
the last dose.

- Concomitant medication likely to produce serious interaction with study drugs
including warfarin type oral anticoagulants and anti-epileptics.